Clinical Trial Update: Rituximab for HTLV-1-associated Myelopathy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating rituximab for HTLV-1-associated myelopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Htlv-1-associated Myelopathy

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: First Affiliated Hospital of Fujian Medical University | Conditions: HTLV-1-associated Myelopathy | Phase 2 | Status: UNKNOWN